Hodgkin’s lymphoma drug to launch soon
Brentuximab vedotin is due to be launched next week (19 November 2012) for the treatment of relapsed or refractory Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma.
The new medicine will be available from Takeda and will be marketed as Adcetris.
Brentuximab vedotin is a monoclonal antibody attached to an antimicrotubule agent that kills the target cancer cells. The antibody is specific for the CD30+ protein expressed on the surface of Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma cells.
Brentuximab vedotin is administered every three weeks by intravenous infusion over 30 minutes at a dose of 1.8mg/kg body weight. Treatment is recommended to continue until disease progression or unacceptable toxicity occurs. In patients with stable (or better) disease a minimum of eight cycles and a maximum of 16 cycles should be completed.
In two open-label, single-arm, multicentre studies, brentuximab vedotin resulted in a 75 per cent response rate in Hodgkin’s lymphoma patients and an 86 per cent response rate in systemic anaplastic large cell lymphoma patients.
The most common side effects of brentuximab vedotin are infections, according to the summary of product characteristics. However a rarer, often fatal condition, progressive multifocal leukoencephalopathy has been reported outside of clinical trials in patients who had also received multiple prior chemotherapy regimens.
Adcetris is indicated for treatment of adult patients with relapsed or refractory CD30+ Hodgkin’s lymphoma following autologous stem cell transplant, or following at least two prior therapies, when autologous stem cell transplant or multi-agent chemotherapy are not a treatment option. It is also indicated for adult patients with relapsed or refractory systemic large cell lymphoma.
Class: Antibody-drug conjugate
Citation: The Pharmaceutical Journal URI: 11111588
Recommended from Pharmaceutical Press